Ilaris and Obsessive-compulsive disorder - a phase IV clinical study of FDA data

Summary:

Obsessive-compulsive disorder is reported as a side effect among people who take Ilaris (canakinumab), especially for people who are male, 2-9 old, also take Colchicine,.

The phase IV clinical study analyzes which people have Obsessive-compulsive disorder when taking Ilaris. It is created by eHealthMe based on reports of 13,051 people who have side effects when taking Ilaris from the FDA, and is updated regularly.

What is Ilaris?

Ilaris has active ingredients of canakinumab. eHealthMe is studying from 13,059 Ilaris users. Check the latest studies of Ilaris.

What is Obsessive-compulsive disorder?

Obsessive-compulsive disorder (an anxiety disorder characterized by intrusive thoughts that produce uneasiness, apprehension, fear, or worry;) is found to be associated with 676 drugs and 1,312 conditions by eHealthMe. Check the latest studies of Obsessive-compulsive disorder.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 16, 2026

13,051 people reported to have side effects when taking Ilaris.
Among them, 13 people (0.1%) have Obsessive-compulsive disorder.

Could Ilaris cause Obsessive-compulsive disorder?

Among these 13 people:

What is the gender of people who have Obsessive-compulsive disorder when taking Ilaris? *

female: 0.0 %
male: 100 %

What is the age of people who have Obsessive-compulsive disorder when taking Ilaris? *

What are other drugs people take besides Ilaris? *

Colchicine: 8 people, 61.54%

What are other side effects people have besides Obsessive-compulsive disorder? *

Nausea And Vomiting: 13 people, 100.00%
Oropharyngeal Pain: 13 people, 100.00%
Drug Ineffective: 13 people, 100.00%
Infection: 13 people, 100.00%
Joint Pain: 13 people, 100.00%
Discomfort: 13 people, 100.00%
Cough: 13 people, 100.00%
Autism Spectrum Disorder (developmental disabilities that can cause significant social, communication and behavioural challenges): 13 people, 100.00%
Nasopharyngitis (inflammation of the nasopharynx): 13 people, 100.00%
Fatigue (feeling of tiredness): 13 people, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Ilaris and have Obsessive-compulsive disorder?

- Check whether Obsessive-compulsive disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ilaris:

Ilaris (13,059 reports)

Browse all side effects of Ilaris:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Obsessive-compulsive disorder:

Obsessive-compulsive disorder (676 drugs)

Browse all the conditions that are associated with Obsessive-compulsive disorder:

Obsessive-compulsive disorder (1,312 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on canakinumab (the active ingredients of Ilaris) and Ilaris (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.